Talimogene laherparepvec (T-VEC) is a herpes simplex virus type 1-derived oncolytic
immunotherapy designed to selectively replicate within tumors and produce granulocyte …

Sentinel lymph node (SLN) biopsy has emerged over the past 2 decades as a rational
approach for staging regional lymph nodes in patients with clinically node-negative …

Here we report a phase 1b clinical trial testing the impact of oncolytic virotherapy with
talimogene laherparepvec on cytotoxic T cell infiltration and therapeutic efficacy of the anti …

Intratumoral (IT) immunotherapy is approved for stage IIIB to IV melanoma 1-5 and under
evaluation in other malignancies with novel immune-stimulatory products. 6-18 …

Purpose We evaluated the combination of talimogene laherparepvec plus ipilimumab
versus ipilimumab alone in patients with advanced melanoma in a phase II study. To our …

Purpose Combining immunotherapeutic agents with different mechanisms of action may
enhance efficacy. We describe the safety and efficacy of talimogene laherparepvec (T-VEC; …

Immunotherapy has revolutionised cancer treatment through restoration of host antitumour
immune response. Immune checkpoint inhibitors (ICIs) confer durable responses in only a …

Background Surgical resection of gastrointestinal stromal tumors (GISTs) has been the most
effective therapy for these rare tumors. Imatinib has been introduced as systemic therapy for …

Purpose: This phase I study assessed the safety, pharmacokinetics (PKs), and efficacy of
MIW815 (ADU-S100), a novel synthetic cyclic dinucleotide that activates the stimulator of IFN …

Background Talimogene laherparepvec is an oncolytic immunotherapy approved in the US,
Europe, Australia and Switzerland. We report the final planned analysis of OPTiM, a …